Skip to main content
. Author manuscript; available in PMC: 2017 Jul 10.
Published in final edited form as: Dev Ophthalmol. 2015 Oct 26;55:46–56. doi: 10.1159/000431141

Fig. 4.

Fig. 4

Complement factors are targets for pharmacologic inhibition in retinal disease. Numerous therapeutic targets for complement pathway inhibition are investigated in preclinical and clinical investigations. Alexion engineered a whole IgG humanized antibody (eculizumab) against C5 which was tested in a phase II trial with negative results. Ophthotech developed a pegylated RNA aptamer (ARC1905/Zimura®) that also neutralizes C5 and is currently in a phase I trial for the combination treatment of polypoid choroidal vasculopathy. Potentia revived a previously described small-molecule inhibitor of C3, compstatin, which completed phase I trials for the treatment of wet AMD with no preliminary signature of efficacy. Genentech has advanced the anti-CFD antibody fragment, lampalizumab, to phase III trials for the treatment of geographic atrophy; 1-year results are anticipated in early 2016 for this important trial.